Publikationen

Grundlegende Voraussetzung für die flächendeckende Verbesserung der Behandlungskonzepte ist die Publikation der Forschungsergebnisse. iOMEDICO unterstützt die internationalen Richtlinien zu Transparenz und Veröffentlichung von medizinischen Forschungsergebnissen.

Wir präsentieren unsere Daten regelmäßig auf nationalen und internationalen Kongressen. Unsere Publikationen erscheinen in wissenschaftlich renommierten, internationalen Fachzeitschriften. Autoren sind die Studienleiter, Prüfärzte mit besonders hoher Patiententeilnahme und Wissenschaftler von iOMEDICO.

TITEL
STUDIE
JAHR
Vinorelbine plus everolimus versus vinorelbine monotherapy as second-line treatment for HER2-negative advanced breast cancer. Final results from the randomized phase II trial vicTORia.

Decker, T., Marschner, N., Welt, A., Riedt, T., Hagen, V., Rauh, J., Klein, D., Potthoff, K., Jähnig, P., Schröder, H., Lerchenmüller, C., 2018.

Oncol Res Treat 41 (suppl4)(V491), 158–159.

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
VICTORIA
2018
Everolimus as second-line therapy for metastatic renal cell carcinoma: final results of phase IV study MARC-2.

M. Staehler, D. Christoph, M. Stöckle, J. Harde, A. Stenzl, D. Klein, I. Benz-Rüd, V. Grünwald, 2018.

Oncol Res Treat 41 (suppl 4)(P610).

Download

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
MARC-2
2018
Final results from IMPROVE: A randomized, controlled, open-label, cross-over phase IV study to determine the patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab for advanced HR+/HER2- breast cancer.

Decker T, Söling U, Hahn A, Maintz C, Kurbacher CM, Rieger L, Chiabudini M, Falkenstein J, Runkel E, Potthoff K., 2018.

Oncol Res Treat 41 (suppl 4)(P916).

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
IMPROVE
2018
Patient-reported outcomes in patients with metastatic renal cell carcinoma treated with systemic first-line therapy: Interim results of the PRO Kidney registry.

Kirste, T., Werner, T., Scheffler, M., Hamm, N., Eckert, R., Pelz, H., Fichter, C., Müller, L., Sahlmann, J., Potthoff, K., 2018.

Oncol Res Treat 41 (suppl 4)(P608).

Download

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
PRO Kidney
2018
Nab-paclitaxel in combination with carboplatin as first line therapy for patients with stage IIIB/IV NSCLC in the real-world setting: Interim results of the NEPTUN study.

Dechow, T., Riera-Knorrenschild, J., Schulz, H., Janssen, J., Chiabudini, M., Koszinowski, S., Potthoff, K., Lang, S., Runkel, E., 2018.

Oncol Res Treat 41 (suppl 4)(P912).

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
NEPTUN
2018
First-line pazopanib in poor-risk patients with metastatic renal cell carcinoma.

Staehler, M., Panic, A., Merling, M., Vannier, C., Hermann, E., Hogrefe, C., Potthoff, K., Grünwald, V., 2018.

Oncol Res Treat 41 (suppl 4)(P606).

Download

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
FLIPPER
2018
Palbociclib in combination with letrozole as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study.

Welslau, M., Zaiss, M., Söling, U., Untch, M., Müller, L., Lüftner, D., Meiler, J., Welt, A., Sahlmann, J., Houet, L., Runkel, E., Vannier, C., Marschner, N., 2018.

Oncol Res Treat 41 (suppl 4)(P919).

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
INGE-B
2018
An observational study to evaluate the effectiveness of OnLife® in improving chemotherapy-induced peripheral neuropathy in patients with colon or breast cancer after end of adjuvant therapy: Design of the STEFANO trial.

Zaiss, M., Uhlig, J., Zahn, M.-O., Decker, T., Lehmann, H., Harde, J., Hogrefe, C., Vannier, C., Marschner, N., 2018.

Oncol Res Treat 41 (suppl 4)(P945).

Indikation: Breast Cancer, Colorectal Cancer, Kolorektalkarzinom, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
STEFANO
2018
Carfilzomib in combination with lenalidomide and dexamethasone or carfilzomib in combination with dexamethasone alone in patients with multiple myeloma who have received at least one prior therapy: Interim results of the non-interventional CARO study.

Knauf, W., Ammon, A., Merling, M., Hurtz, H.-J., Vannier, C., Schulz, H., Marschner, N., Riedt, T., Potthoff, K., 2018.

Oncol Res Treat 41 (suppl 4)(P572).

Download

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CARO
2018
Does progression influence the quality of life? – Data from patients with advanced breast cancer from the MaLife-Project.

Marschner N., Söling, U., Scholz, H., Azeh, I., Chiabudini, M., Kruggel, L., Jänicke, M., 2018.

Oncol Res Treat 41 (suppl.4) (V493)

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TMK
2018